Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a medicine called daclizumab in people with a type of eye inflammation linked to juvenile idiopathic arthritis (JIA) — a condition where the joints and sometimes the eyes become inflamed in children. Six participants were enrolled in the study overall. Three participants completed the trial, and three did not finish. The trial was measuring two things: whether daclizumab could reduce eye inflammation by a meaningful amount, and whether any serious unwanted medical events (known as serious adverse events) occurred while taking the medicine. The reported data shows that, out of the six participants, five were reported to have achieved a significant reduction in their eye inflammation — specifically, a drop of at least two steps on a scale used to measure inflammation in the front of the eye (where 0 means almost no inflammation and 4+ means very heavy inflammation). This reduction also had to occur while the participant was using eye drop steroids fewer than three times a day. Regarding safety, the reported data shows that one out of the six participants experienced a serious adverse event during the study, though the specific nature of that event was not detailed in the data provided here. It is worth noting that this was a very small trial with only six participants, so the numbers are based on a limited group of people. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 19664754) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 6 and 18 years old (inclusive)
- You have been diagnosed with eye inflammation (uveitis) that is linked to a condition called juvenile idiopathic arthritis (JIA), and it requires anti-inflammatory treatment given 3 or more times a day
- Your uveitis is still considered active even while on your current treatment
- There is a measurable level of inflammation (at least grade 1+) in the front part of at least one eye
- Your uveitis may or may not currently be treated at the time of joining the study
- You have usable vision of at least 20/640 or better in at least one eye
- Your kidney and liver function test results are normal or only mildly abnormal, within specific limits set by the study (confirm with trial site)
- You agree not to have any planned, non-urgent eye surgery (such as cataract removal) during the first 6 months of the study
- Your blood count shows enough of a type of white blood cell called neutrophils (above 750) (confirm with trial site)
- You are not currently pregnant or breastfeeding
- If you are sexually active and could become pregnant or father a child, you agree to use an acceptable form of birth control during the study and for 6 months after treatment ends
- A parent or legal guardian is able to read, understand, and sign a consent form on your behalf, and you are willing to sign an assent form yourself
- You have already been diagnosed with juvenile rheumatoid arthritis or JIA for some time (not newly diagnosed) and have already received treatment for your uveitis
- You are able to have a specific eye examination called slit lamp biomicroscopy to assess eye inflammation
- You are able to follow and meet all the requirements of the study
- You are up to date on all recommended childhood vaccinations
Who may not be able to join:
- You are under 6 years of age
- You have previously been treated with a specific type of medication called an IL-2 directed monoclonal antibody, or any experimental drug that could affect how this study measures safety or effectiveness
- You have a history of or have been diagnosed with a condition called Behçet's disease
- You currently have a significant active infection
- You have been diagnosed with cancer (other than a certain type of skin cancer) within the past 5 years
- You have used an eye drop medication called latanoprost (Xalatan) within two weeks before joining the study, or are likely to need it
- You cannot receive fluorescein dye (a dye used in certain eye tests) for medical reasons
- There is cloudiness in your eye that prevents doctors from properly assessing your eye inflammation
- You are female and are currently pregnant or breastfeeding
- You are not willing to use contraception during the study and for 6 months after treatment ends, if you could become pregnant or father a child
- You have serious active infections, or a history of serious infections that keep coming back
- You show signs of a related condition affecting the spine or where tendons attach to bones (confirm with trial site)
- Your joint or body-wide inflammation is severe enough that it immediately requires adding or increasing systemic anti-inflammatory medications
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With a Two-step Reduction in Inflammation; Number of Participants Reporting a Serious Adverse Event (SAE)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.